探索设计mRNA疫苗的计算方法,以对抗疫苗和Mopox病毒
Elijah K Oladipo1,2, Olanrewaju D Oyelakin1, Abdulsamad O Aiyelabegan1
1Division of Vaccine Design and Development, Helix Biogen Institute, Ogbomoso, Oyo State, Nigeria.
Immunity, inflammation and disease
|August 16, 2024
概括
一种针对Mpox和vaccinia病毒的新型信使RNA (mRNA) 疫苗显示出有前途. 计算分析表明它是安全和有效的,等待进一步验证.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 使者RNA (mRNA) 疫苗提供了一种有效的抗感染策略,诱导强大的先天性和幽默性免疫反应.
- 它们促进宿主细胞介导的病原体基因表达和抗原呈现,与传统疫苗不同.
研究的目的:
- 设计和计算评估一种新型mRNA疫苗候选物,用于对抗poxviridae感染,特别是mpox和vaccinia病毒.
- 通过in silico方法识别用于疫苗构造开发的关键病毒基因,并确保疫苗的安全性和有效性.
主要方法:
- 选择的疫苗和Mopox病毒基因 (E8L,E7R,H3L) 用于疫苗设计,利用生物信息学生成和选择28种抗原和免疫原表位.
- 纳入了必不可少的mRNA组件 (5'帽,UTRs,辅助剂,多A尾) 并进行了体安全评估 (人类同类学,免疫模拟).
- 评估了与TLR受体 (2,3,4,9) 的疫苗结合亲和力,并进行了分子动力学模拟以预测复杂的稳定性.
主要成果:
- 在 silico 设计的 mRNA 疫苗表现出有希望的抗原性,无毒性和无过敏性.
- 计算分析表明,该疫苗在预防Mpox和vaccinia病毒感染方面是安全和有效的,比其他in silico设计更优越.
- 疫苗结构的分子量为198kDa,分子公式为C8901H13609N2431O2611S48,表明73%的人口覆盖率.
结论:
- 开发的mRNA候选疫苗为对抗Mpox和vaccinia病毒感染提供了一个有前途的战略.
- 进一步的体内和体外研究是必要的,以全面验证疫苗的潜力和疗效.
相关概念视频
Leaky Scanning
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...


